Navigation Links
Study Shows Ixabepilone Demonstrated Clear Activity in Patients,with Metastatic Breast Cancer Resistant to Anthracycline, Taxane,,and Capecitabine

- Phase II Results Published in the Journal of Clinical Oncology -

NEW YORK, July 06, 2007 /PRNewswire-FirstCall/ -- Results from a Phase II study - which will be published in the August 10, 2007 issue of the Journal of Clinical Oncology (JCO) and are now available as an Early Release Article at www.jco.org - demonstrate that ixabepilone, a Bristol-Myers Squibb Company investigational compound, has activity in patients with metastatic breast cancer whose tumors were resistant to three types of standard chemotherapy (anthracycline, taxane, and capecitabine). Currently, there are few proven treatment options available to patients with breast cancer whose disease has rapidly progressed through or whose disease is not responding to prior treatment with approved chemotherapies. This study was one of five Phase II ixabepilone studies published in this issue of JCO, including three additional studies in metastatic breast cancer and one in non-small cell lung cancer.

"Drug resistance is a major concern in treating patients with advanced disease," said Renzo Canetta, vice president, Oncology Global Clinical Research, Bristol-Myers Squibb. "The results of this study are important as they provide valuable information about this investigational compound and its potential in patients with advanced breast cancer that is no longer responding to any of the current U.S. approved chemotherapy treatments."

The 126 patients enrolled in the single-arm Phase II study (CA163081) had heavily pretreated, advanced metastatic breast cancer, which had progressed through three prior therapies (anthracycline, taxane and capecitabine). The primary endpoint was objective response rate, which is an assessment of the response to treatment as determined by the independent radiology facility (IRF). Secondary efficacy endpoints included duration of response, time to response, progres
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:4/24/2015)... - T-Bird Pharma Inc. (TSXV:TPI) ("T-Bird" or the "Company"), ... marijuana products and a licensed producer ("LP") to cultivate ... Canada ) ("MMPR"), is pleased to announce ... closed the transaction announced on March 11, 2015 with ... Transfer") a total of 20,156,790 common shares of T-Bird ...
(Date:4/24/2015)... , April 24, 2015  Blueprint Medicines ... a selective and potent inhibitor of fibroblast growth ... in models of hepatocellular carcinoma (HCC) that are ... candidate, BLU-554 induced complete tumor regression in a ... FGFR4-activating ligand at the highest dose levels. These ...
(Date:4/23/2015)... 2015  ResMed Inc. (NYSE: RMD ) today ... Revenue for the quarter was $422.5 million, a 6 ... 2014 (a 13 percent increase on a constant currency ... 1 percent compared to the quarter ended March 31, ... $0.64, an increase of 2 percent compared to the ...
Breaking Medicine Technology:T-Bird Pharma Inc. Announces Closing of Transaction with Medna Biosciences 2T-Bird Pharma Inc. Announces Closing of Transaction with Medna Biosciences 3Blueprint Medicines Presents New Preclinical Data Demonstrating Its Drug Candidate BLU-554 Induces Significant Tumor Regression in Models of Hepatocellular Carcinoma 2Blueprint Medicines Presents New Preclinical Data Demonstrating Its Drug Candidate BLU-554 Induces Significant Tumor Regression in Models of Hepatocellular Carcinoma 3ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 11ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 12ResMed Inc. Announces Results for the Third Quarter of Fiscal Year 2015 13
... INC. (NYSE: RMD ), announced today that on ... the third quarter and nine months of fiscal year 2011, ... will be issued after 1:00 p.m. Pacific Time and the ... its results, market trends, and future outlook. (Logo: ...
... NeuroVasx announced today that the FDA has approved ... Device (HDE) for the treatment of large, giant and ... to treat.  The HDE allows for the treatment of ... (Logo: http://photos.prnewswire.com/prnh/20110405/CG77724LOGO ) Christopher ...
Cached Medicine Technology:ResMed Announces Conference Call and Webcast to Discuss Third Quarter 2011 Results 2NeuroVasx Receives FDA Approval for cPAX Aneurysm Treatment System 2
(Date:4/25/2015)... Sports controversies continue to revolve around issues of abuse and violence. ... the Miami Dolphins and Richie Incognito, or off the field and ... abuse case. In a recent episode of SCI TV , ... locker room culture on teams. He examines what worked for the ... improve the locker room as a work place. , Steele ...
(Date:4/24/2015)... NY (PRWEB) April 24, 2015 Constellations ... living residence in Westchester County. Just 35 miles from ... transition individuals back into everyday life while recovering from ... May 7, 2015, will allow therapists, doctors and treatment ... and learn more about the opportunities offered by Constellations ...
(Date:4/24/2015)... April 24, 2015 Carvers' goal ... have a successful biking day in Breck. , ... five minutes walking distance from Breckenridge, this family-owned ... in both Breckenridge bike rentals ( http://www.breckenridgeskishop.com/en/rent-equipment ) ... offer extensive bike rentals in May 2015. With ...
(Date:4/24/2015)... CA (PRWEB) April 24, 2015 On ... sitting down in an interview with ItsNotAboutMe.TV contributor Karen ... Recovery, a holistic treatment center for addiction, of which ... ceremonies and festivals throughout the year, the EcoLuxe Lounge ... providers of eco-friendly and socially conscious products and services. ...
(Date:4/24/2015)... Anchor Health Administrators (Anchor), specialists in Long-Term Care ... exclusive agreement with LTC Solutions for All LLC (SFA) ... , Anchor has more than 18 years of experience ... and is currently the designated advocate for the American ... member benefit. , “I am very pleased to be ...
Breaking Medicine News(10 mins):Health News:David Steele Discusses Locker Room Culture on SCI TV 2Health News:David Steele Discusses Locker Room Culture on SCI TV 3Health News:Constellations Recovery Opens The First Luxury Sober Living Residence in Westchester New York 2Health News:Constellations Recovery Opens The First Luxury Sober Living Residence in Westchester New York 3Health News:Carvers Breckenridge Bike Rentals Offers Demo Mountain, Tandem, Bike Path Cruiser & JR. Bikes in May 2015 2Health News:Karen Salkin Talks with Per Wickstrom at the 2015 EcoLuxe Lounge and the "Salute to the Oscars" Celebration 2
... Maureen Salamon HealthDay Reporter , THURSDAY, Sept. 29 ... every corner of the globe, new research suggests that folks ... the workday progresses, regardless of where they live. The ... of 2.4 million people in 84 countries over two years, ...
... FRIDAY, Sept. 30 (HealthDay News) -- Unspoken clues -- ... according to a new study. Researchers from the University ... an impact on how patients view their relationship with ... The findings could help doctors better understand how they ...
... Franklin was right, at least on the healthy part. "Early to ... of early-bird Australian youths keep slimmer and more physically active than ... of sleep. A study in the Oct. 1 issue of ... of 2,200 Australian participants, ages 9 to 16, and compared their ...
... Picky eating is normal in children, but a pediatric feeding ... a child,s physical and mental development, an expert says. ... clinical director of the Pediatric Feeding Disorders Program at the ... reject certain foods but still has a nourishing diet. Children ...
... , THURSDAY, Sept. 29 (HealthDay News) --,New ... in a large-scale analysis of genetic data related to ... Philadelphia examined six large databases for DNA data from ... healthy people. In addition to validating results from ...
... LOS ANGELES (Sept. 29, 2011) Six leaders in ... will be key presenters at the world,s largest interdisciplinary ... The World Stem Cell Summit, co-sponsored by the ... the global stem cell and regenerative medicine community. ...
Cached Medicine News:Health News:Twitter Reflects World's Changing Moods 2Health News:Twitter Reflects World's Changing Moods 3Health News:Doctors Consider Nonverbal Cues in Medical Decisions 2Health News:Early to bed and early to rise -- study suggests it's keeping kids leaner 2Health News:Does Your Picky Eater Have a 'Feeding Disorder'? 2Health News:Cedars-Sinai scientists, physicians to be key presenters at World Stem Cell Summit 2Health News:Cedars-Sinai scientists, physicians to be key presenters at World Stem Cell Summit 3
This camouflaging lens features the solid black stripes of the lightning fast African zebra, on a white iris background....
Sphere Introducer...
Reusable cannula with .90 mm (20 g) shaft, tapering to .30 mm (30 g). Angled 125 3 mm from tip and flattened for easy insertion into the subretinal space....
... tip cannula allows atraumatic access ... for aspiration of subretinal fluids. ... beyond end of cannula. ... secure connection to a backflush ...
Medicine Products: